Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 6/20 | 0.62 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.62 |
| ▸ | BCR | P11274 | 6/20 | 0.62 |
| ▸ | RXRA | P19793 | 2/20 | 0.55 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.50 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.50 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.50 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.50 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.50 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.50 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13079694 | 0.88 | NPC1 (0.57) | ABL1ABCB1BCRERN1NPC1 | |
| SCHEMBL12386386 | 0.88 | NPC1 (0.57) | ABL1ABCB1BCRERN1NPC1 | |
| SCHEMBL26784179 | 0.88 | ABL1 (0.49) | ABL1ABCB1BCRRXRACYP4F2 | |
| SCHEMBL6285826 | 0.85 | MAOB (0.59) | NPC1TP53MAPK1CASP3RAB9A | |
| SCHEMBL378856 | 0.85 | ABL1 (0.58) | ABL1ABCB1BCRRXRACYP1A1 | |
| SCHEMBL31222693 | 0.83 | MAOB (0.66) | ABL1ABCB1BCRCYP1A1CYP1A2 | |
| SCHEMBL31222694 | 0.83 | MAOB (0.66) | ABL1ABCB1BCRCYP1A1CYP1A2 | |
| SCHEMBL2604700 | 0.83 | MAOB (0.66) | ABL1ABCB1BCRCYP1A1CYP1A2 | |
| SCHEMBL11791322 | 0.82 | CALM1 (0.55) | ABL1ABCB1BCRAKR1B1 | |
| SCHEMBL25366032 | 0.80 | CYP11B1 (0.60) | CYP1A1CYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | PTGER1, PTGIR, PTGDR2 | ABL1 3553/4885ABCB1 3380/4885BCR 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.